Xenikos
Manufacturing · Netherlands · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Wilhelminasingel 14, Nijmegen, Gelderlan...Phone Number
+31 243000100Website
www.xenikos.comRevenue
$6.3 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Xenikos
Xenikos, a private, clinical-stage biopharmaceutical company, is focused on developing innovative immunotherapies, based on toxin-conjugated antibodies, which are designed to quickly and safely reset the immune system in patients with a severe immune disease or post-transplantation rejection. The company was founded in 2009 and is headquartered in Gelderland, Netherlands.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Xenikos your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Xenikos has new funding data
Click to see if Xenikos had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Xenikos
Product Launch: Get notified when Xenikos launches new products
Check if Xenikos has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Xenikos, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Xenikos recently announced quarterly report
Check out if Xenikos is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Xenikos
Find more new buyers
Company Profile Activity
Activity Insights
Xenikos is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Xenikos is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Xenikos.
Xenikos financials insights
Gather financial insights about Xenikos, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series B
$30M
2021
Debt
$47.3M
Xenikos Tech Stack
A closer look at the technologies used by Xenikos
See more technologies
Most Recent Scoops
New Hire
Executive Move
Funding
Left Company
Executive Move
Left Company
Left Company
Executive Move
Xenikos News & Media
Xenikos Appoints Hassan Aly, MD, PhD as Chief Medical Officer
NIJMEGEN, The Netherlands, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Xenikos B.V., a privately-held biotechnology company that develops innovative immunotherapies for treating patients with severe immune diseases and post-transplant rejection, today announced the appointment of Hassan Aly, MD, PhD, as Chief Medical Officer. Dr. Aly brings over three decades of practice in the treatment of hematological malignancies, including allogeneic hematopoietic stem cell transplantation (HSCT) and 10 years of expXenikos Secures €40 Million in Convertible Debt Financing, Veloxis Pharmaceuticals Joins as Strategic Investor
NIJMEGEN, the Netherlands, Sept. 8, 2021 /PRNewswire/ -- Xenikos B.V., a clinical-stage biopharmaceutical company currently developing a novel therapy for treating immune related disorders, announced today the closing of €40 million in convertible debt consisting of two equal tranches of...Xenikos Announces T-Guard® Phase 3 Clinical Update and Outlines 2021-2022 Corporate Objectives
Company Plans to Commence New Pivotal, Randomized Phase 3 Study Evaluating T-Guard® Versus Ruxolitinib in Patients with Grade III or IV Steroid-refractory Acute Graft-Versus-Host Disease in Second Half of 2021 Positive Results Expected to Support Both FDA and EMA Regulatory Submissions NIJMEGEN, the Netherlands, July 19, 2021 (GLOBE NEWSWIRE) -- Xenikos B.V., a privately-held biotechnology company that develops innovative immunotherapies for treating patients with severe immune disease and post-Aruvant appoints Stan Musial as CFO
Most recently, Mr. Musial served as the CFO and chief business officer of Xenikos B.V., a clinical-stage biopharmaceutical company focused on developing
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Xenikos
Sign Up For FreeTo access detailed company insights
Xenikos, a private, clinical-stage biopharmaceutical company, is focused on developing innovative immunotherapies, based on toxin-conjugated antibodies, which are designed to quickly and safely reset the immune system in patients with a severe immune disease or post-transplantation rejection. The company was founded in 2009 and is headquartered in... Read More
